
    
      Patients diagnosed with AIN 2/3 will be enrolled sequentially in treatment cohorts receiving
      different doses of Artesunate suppositories administered trans-anally. Doses of escalation
      will be 200 mg, 400 mg, and 600 mg. Treatment cohorts will consist of 2 or 3 cycles at each
      dose level. Suppositories will be administered daily for 5 days. Five days constitutes 1
      cycle. Up to 3 cycles will be administered at Weeks 0, 2, and 4.
    
  